Narrative review / 2019
A review reports that about 130 human clinical trials of resveratrol have yielded varying results, alongside a pristine safety profile.
This narrative review discusses the history and development of resveratrol research. Around 130 human clinical trials have been conducted or are underway with varying results, potentially due to disparate doses ranging from approximately 5 to 5,000 mg/day and variable experimental settings. Molecular targets are numerous without a dominant mechanism, but resveratrol maintains a pristine safety profile and widespread use as a dietary supplement. The author suggests future investigation is warranted, noting potential promise for topical preparations and conditions responsive to anti-inflammatory action or direct exposure, such as colon cancer prevention.
- Study type
- Narrative review
- Who was studied
- Human clinical trial participants across approximately 130 trials
- What was measured
- Outcomes across varying human clinical trials and safety profile
THE PAPER
Resveratrol: Twenty Years of Growth, Development and Controversy.
Pezzuto JM. Biomol Ther (Seoul), 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.